Twist Bioscience: Anthropic Deal and Record Figures Boost the Stock
Reading Time: 3 minutes
New AI catalyst: Anthropic names Twist Bioscience as an independent evaluator for protein design tests with the AI models Claude Opus 4.8 and Mythos Preview. Strong operational dynamics: In the third quarter, the company recorded its 14th consecutive revenue record and is aiming for EBITDA break-even soon. In-demand shovel manufacturer: The physical validation of AI-generated DNA establishes the company as an indispensable partner in the biotech sector. The American biotechnology pioneer Twist Bioscience has firmly established...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
